SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. References
  7. Supporting Information

Advanced glycation endproducts (AGEs) accumulate in patients with diabetes, yet the link between AGEs and inflammatory and fibrogenic activity in nonalcoholic steatohepatitis (NASH) has not been explored. Tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) is at the center of inflammatory processes. Because the main natural regulator of TACE activity is the tissue inhibitor of metalloproteinase 3 (Timp3), we hypothesized that AGEs induce TACE through nicotinamide adenine dinucleotide phosphate reduced oxidase 2 (NOX2); and the down-regulation of Sirtuin 1 (Sirt1)/Timp3 pathways mediate fibrogenic activity in NASH. The role of NOX2, Sirt1, Timp3, and TACE was evaluated in choline-deficient L-amino acid defined (CDAA) or Western diet (WD)-fed wild-type (WT) and NOX2−/− mice. To restore Timp3, mice were injected with adenovirus (Ad)-Timp3. Sirt1 and Timp3 expressions were studied in livers from NASH patients, and we found that their levels were significantly lower than in healthy controls. In WT mice on the CDAA or WD, Sirt1 and Timp3 expressions were lower, whereas production of reactive oxidative species and TACE activity significantly increased with an increase in active TNF-α production as well as induction of fibrogenic transcripts. Ad-Timp3 injection resulted in a significant decline in TACE activity, procollagen α1 (I), alpha smooth muscle actin (α-SMA) and transforming growth factor beta (TGF-β) expression. NOX2−/− mice on the CDAA or WD had no significant change in Sirt1, Timp3, and TACE activity or the fibrosis markers assessed. In vitro, AGE exposure decreased Sirt1 and Timp3 in hepatic stellate cells by a NOX2-dependent pathway, and TACE was induced after exposure to AGEs. Conclusion: TACE activation is central to the pathogenesis of NASH and is mediated by AGEs through NOX2 induction and down-regulation of Sirt1/Timp3 pathways. (Hepatology 2013;58:1339–1348)

Abbreviations
Ad

adenovirus

AGEs

advanced glycation endproducts

ALT

alanine aminotransferase

BSA

bovine serum albumin

CDAA

choline-deficient L-amino acid defined

CSAA

choline-supplemented L-amino acid-defined

DM

diabetes mellitus

FBS

fetal bovine serum

GA

glycolaldehyde

GFP

green fluorescent protein

HCs

healthy controls

HSCs

hepatic stellate cells

IP

immunoprecipitation

IR

insulin resistance

KCs

Kupffer cells

KO

knockout

NADPH oxidase

nicotinamide adenine dinucleotide phosphate reduced oxidase

NASH

nonalcoholic steatohepatitis

NOX2

NADPH oxidase 2

OS

oxidative stress

PBS

phosphate-buffered saline

PKC

protein kinase C

pfu

plaque-forming units

qPCR

quantitative polymerase chain reaction

RAGE

receptor of advanced glycation endproducts

ROS

reactive oxidative species

siRNAs

small interfering RNAs

Sirt1

Sirtuin 1

α-SMA

alpha smooth muscle actin

TACE

TNF-α-converting enzyme

TG

triglyceride

TGF-β

transforming growth factor beta

Timp3

tissue inhibitor of metalloproteinase 3

TNF-α

tumor necrosis factor alpha

WD

Western diet

WT

wild type.

Diabetes mellitus (DM) is a major risk factor for disease progression with necroinflammation and fibrosis advancing to cirrhotic-stage nonalcoholic steatohepatitis (NASH).[1, 2] The factors implicated in this progression are poorly understood, specifically the effects of diabetes or insulin resistance (IR) on fibrogenesis. Advanced glycation endproducts (AGEs) are produced by a nonenzymatic glycation of serum proteins, and these modifications significantly influence the structure and function of key protein targets.[3, 4] AGEs are implicated in diabetic nephropathy, vascular complications, and retinopathy,[5, 6] but their role in inducing inflammatory or fibrogenic changes in the liver have not been adequately explored. Sirtuin 1 (Sirt1) belongs to the class III family of histone deacetylases, and its decreased activity was shown to be linked to the development of NASH.[7] Accumulating evidence suggests that, in NASH, hepatic lipid metabolism pathways are affected by Sirt1[8] and low levels of Sirt1 are implicated in the development of steatosis in animals.[9] Moreover, in the heterozygous Sirt1 knockout (KO) model, when chronically challenged with a 40% fat diet, mice became obese and insulin resistant, displaying increased serum cytokine levels and developing hepatomegaly.[10] Hepatic metabolomic analyses revealed that Sirt1 heterozygous mice had elevated gluconeogenesis and oxidative stress (OS).[11] Among the targets of Sirt1 is tissue inhibitor of metalloproteinases 3 (Timp3),[12] a key regulator and inhibitor of the tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE; also called A Metalloprotease and Disintegrin 17) activity. Timp3−/− mice have been described to develop vascular inflammation by increased TNF-α[13] as well as hepatic steatosis.[14]

In this study, we showed that exposure to AGEs leads to down-regulation of Sirt1 and Timp3 in hepatic stellate cells (HSCs) by activation of NADPH oxidase (nicotinamide adenine dinucleotide phosphate reduced oxidase) 2 (NOX2) and the release of reactive oxidative species (ROS). Accordingly, wild-type (WT) mice fed the choline-deficient L-amino acid defined (CDAA) or western diet (WD) showed decreasing Sirt1, Timp3 expression, and an increase in TACE activity, TNF-α production, and increased fibrogenic activity. Correction of the low TIMP3 levels by injection of adenoviral (Ad)-Timp3 into CDAA or WD-fed mice reduced TACE activity, TNF-α, expression of the receptor of advanced glycation endproducts (RAGE), and fibrogenic response. NOX2−/− mice on NASH diets did not develop increased TACE activity or fibrogenic response. In summary, these data suggest an important role of AGEs in NOX2-mediated induction of TACE, TNF-α, and fibrogenic activity during NASH progression.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. References
  7. Supporting Information
Liver Biopsy Samples

Liver biopsy samples were obtained from the University of California Davis Cancer Center Biorepository (Sacramento, CA) funded by the National Cancer Institute (Bethesda, MD). Samples from 6 different patients and 6 normal livers were tested. All patients had IR or DM.

Animal Studies

C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) or B6.129S-Cybbtm1Din/J (NOX2−/−; Jackson Lab) were given choline-supplemented L-amino acid-defined (CSAA) or CDAA diet (Dyets Inc., Bethlehem, PA) for 10 weeks or control chow. Both diets contain higher calories, fat, and carbohydrates than standard chow.[15] The fast-food (“Western”) diet contains 40% energy as fat (12% saturated fatty acids, 2% cholesterol; AIN-76, Western diet; TestDiet, St. Louis, MO) and is supplemented with high-fructose corn syrup (42 g/L).[16] To test for the role of Timp3 in TACE regulation, Ad-Timp3 was injected on week 8 through the tail vein (2 × 107 plaque-forming units [pfu]/200 uL of phosphate-buffered saline [PBS]; Applied Biological Materials Inc., Richmond, British Columbia, Canada). As control, Ad-GFP (green fluorescent protein; 2 × 107 pfu/200 uL; Vector Biolabs, Philadelphia, PA) was used. In a group of mice, GdCl3 (10 mg/kg in saline; Sigma-Aldrich, St. Louis, MO) was injected intraperitoneally every other day throughout the experiment to inhibit macrophages in both models. Serum and liver tissue were collected and alanine aminotransferase (ALT) and bilirubin were tested. Tissue was processed for the further assays. Animals were housed in facilities approved by the National Institutes of Health (Bethesda, MD). All procedures were reviewed and approved by the animal welfare committee of the University of California Davis.

Cell Culture

Primary HSCs were isolated either from C57BL/6 mice or Sprague-Dawley rats as described previously.[17] Cells were cultured in medium 199/20% fetal bovine serum (FBS). Primary HSCs were used for experiments within the first 3 days after isolation. Cells were exposed to AGEs (50 μg/mL) or bovine serum albumin (BSA) in serum-free medium for 16 hours and/or transfected with small interfering RNAs (siRNAs).

For siRNA transfection, primary rat HSCs were cultured as described above for 1 day, then the medium was changed to Dulbecco's modified Eagle's medium, 0.5% FBS. HSCs were transfected with the siRNA to Sirt1 or Timp3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA) or scrambled siRNA using the RiboJuice transfection reagent (EMD Chemicals Inc., Darmstadt, Germany), according to the manufacturer's instructions.

Results

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. References
  7. Supporting Information
Exposure to AGEs Induces Sirt1 and Timp3 Down-Regulation by NOX2 in Primary HSCs

Activation of NOXs is one of the main sources of ROS in activated HSCs. We have previously shown that NOX2 is an important factor in HSC transdifferentiation.[18] To study the role of AGEs in ROS production, primary cells were transfected with NOX2 or scrambled siRNA and incubated in serum-free conditions with glycolaldehyde (GA)-derived AGEs for 16 hours. Superoxide production was significantly increased in control (untransfected) and scrambled siRNA-transfected HSCs (Fig. 1A; 1.74- ± 0.13-fold; P < 0.05), whereas this was attenuated in NOX2 siRNA-transfected cells (Fig. 1A). To study the effects of AGEs/ROS on Sirt1 and Timp3 expression, real-time quantitative polymerase chain reaction (qPCR) was done on cells from the above-described experiment. Sirt1 and Timp3 were down-regulated in response to AGEs in a NOX2-dependent manner (Fig. 1B; 0.38- ± 0.14-fold; P < 0.05; 0.58- ± 0.10-fold; P < 0.05, respectively). To test whether Sirt1 directly targets Timp3 in primary HSCs, cells were transfected with Sirt1 siRNA, and Timp3 expression was found to be down-regulated in response to inhibition of Sirt1 (0.36- ± 0.16-fold; N = 3; P < 0.05; Fig. 1C).

image

Figure 1. AGEs induce ROS production and down-regulate Sirt1 and Timp3 expression by NOX2. Primary HSCs were treated with either scrambled siRNA or NOX2 siRNA for 48 hours, followed by GA-derived AGE exposure or BSA (control) for 16 hours. Lucigenin assay showed that superoxide production was significantly increased by AGEs in both untransfected (NT) (*P < 0.05) or scrambled siRNA-transfected (Scr) HSCs (*P < 0.05), whereas knockdown of NOX2 attenuated superoxide production (mean ± SE; *P < 0.05; N = 4) (A). Sirt1 and Timp3 mRNA expression were assessed by real-time qPCR. After treating with AGEs for 16 hours, Sirt1 and Timp3 mRNA levels decreased in NT and Scr siRNA-transfected HSCs (shown in fold expression; *P < 0.05; N = 4), but not in NOX2 siRNA-transfected HSCs (B). Timp3 mRNA expression decreased in response to siRNA knockdown of Sirt1 (*P < 0.05; N = 4), as assessed by real-time qPCR (C). SE, standard error of the mean; mRNA, messenger RNA.

Download figure to PowerPoint

AGEs Induce TACE Activity in HSCs

Because Timp3 is the main natural inhibitor of TACE activity, we next examined whether TACE could be induced by AGEs. This was studied by two different methods: fluorometry (Fig. 2A) and immunoprecipitation (IP) with western blotting to assess TACE tyrosine phosphorylation, which correlates with the active state of the enzyme (Fig. 2B). TACE activity was induced by AGEs in scrambled siRNA-transfected HSCs (1.48- ± 0.06-fold; P < 0.01; Fig. 2A), and this was significantly attenuated in NOX2 siRNA-transfected HSCs (1.10- ± 0.09-fold; P < 0.05). In addition, inhibiting Sirt1 by siRNA also resulted in an increase in TACE activity (1.43- ± 0.10-fold; P < 0.05), which was further increased by AGEs (2.29- ± 0.23-fold; P < 0.05). TACE was phosphorylated after exposure of HSCs to AGEs, indicating the activated state of the enzyme (Fig. 2B). To discern whether the other major cell types in the liver contribute to AGE-induced TACE activation, primary hepatocytes, HSCs, and Kupffer cells (KCs) were incubated either with BSA or AGEs. TACE activity of hepatocytes was very low and not induced by AGEs (Fig. 2C). Only HSCs responded with a significant increase (1.73- ± 0.14-fold; P < 0.05), and whereas the baseline activity of KCs was higher than that of hepatocytes; no induction was noted after incubation with AGEs.

image

Figure 2. AGEs induce TACE activity in HSCs. After transfection with scrambled (Scr) siRNA, NOX2 siRNA, or SirT1 siRNA for 48 hours, primary HSCs were exposed to AGEs or BSA for 16 hours, and TACE activity was studied by fluorometry. TACE activity increased after AGE treatment in both nontransfected (mean ± SE; *P < 0.05; N = 4) and Scr siRNA-transfected (**P < 0.01; N = 4) groups. This was significantly attenuated in NOX2 siRNA-transfected cells (*P < 0.05, N = 4). TACE activity was also induced in response to knockdown of Sirt1 (*P < 0.05; N = 4) (A). TACE activity was also analyzed by IP and western blotting with anti-p-tyrosine. TACE was phosphorylated after exposure to AGEs (B). TACE activity was tested in isolated primary hepatocytes, HSCs, and KCs after incubation with BSA or AGEs. Only HSC TACE activity was significantly induced by AGEs (mean ± SE; *P < 0.05; N = 3). Hepatocytes had a very low TACE activity, whereas KCs did not exhibit induction after AGEs (C). SE, standard error of the mean.

Download figure to PowerPoint

Sirt1 and Timp3 Are Down-Regulated in Livers of Patients With NASH

To study Sirt1 and Timp3 in human livers with NASH, real-time qPCR was performed on liver biopsy samples from different patients with grade 2-3, stage 3-4 NASH, and healthy controls (HCs; Fig. 3). The patients represented here had either IR with fasting hyperglycemia or type II DM. Expression of both Sirt1 and Timp3 were significantly decreased in NASH livers, compared to normal HCs (expressed as fold over control: 0.47- ± 0.11-fold; P < 0.05; and 0.24- ± 0.07-fold; P < 0.01, respectively; N = 6; Fig. 3). Expression of RAGE was also significantly increased in patients with NASH (3.93- ± 0.2-fold; P < 0.05).

image

Figure 3. Sirt1 and Timp3 were down-regulated, whereas RAGE expression was induced in NASH patients. Real-time qPCR was performed on liver samples from patients with NASH and HCs. Sirt1 and Timp3 were significantly down-regulated in livers with NASH (data expressed as fold over values from HCs, which was set as 1; mean ± SE; *P < 0.05; **P < 0.01, respectively; N = 6). Expression of RAGE was significantly increased in NASH patients (**P < 0.01). SE, standard error of the mean.

Download figure to PowerPoint

NOX2-Dependent ROS Production Is Increased in Two Different Diet Models of NASH and Is Involved in the Regulation of Sirt1 and Timp3

To recapitulate our in vitro findings, WT or NOX2−/− mice were fed either with CDAA, CSAA, or WD. The CDAA model was shown to recapitulate the features of human NASH with IR, inflammatory cell infiltration, hepatocyte death, and liver fibrosis,[19, 20] whereas mice on the CSAA diet mainly develop steatosis, but no necroinflammation or fibrosis. The advantage of using the CSAA/CDAA model is that we can correlate our findings to a model resulting in simple steatosis or progressive NASH. To confirm our findings, we also performed experiments in mice fed the WD supplemented with high fructose.[16] This diet was shown to have higher fidelity to human pathophysiology, with mice exhibiting significant weight gain, metabolic syndrome, and diabetes and histologically developing ballooning, lipoapoptosis, necroinflammation, and fibrosis. Body weight has increased similarly both in WT and NOX2−/− mice on both NASH diets (Fig. 4A). WT mice on CDAA or WD had significantly increased ALT (P < 0.01), compared to mice on the CSAA or control chow diet. Mice on CDAA and WD had increased glucose levels (216.0 ± 36.2 mg/dL and 239.4 ± 12.8 mg/dL, respectively), and these diets were previously shown to induce impaired glucose tolerance or diabetes.[15, 16] AGEs were increased in both diet models in WT but not in the NOX2−/− mice (Supporting Fig. 1). The increase in bilirubin in WT CDAA mice may reflect impaired synthetic function, because these mice had more-severe steatohepatitis and fibrosis. In NOX2−/− mice, ALT showed an increasing trend on NASH diets, compared to baseline, albeit not significant, and below the level of liver injury observed in WT mice, whereas bilirubin had not changed. On histology, all mice on CDAA or WD displayed increased steatosis (Fig. 4B).

image

Figure 4. NOX2-dependent ROS production was increased in two diet models of NASH and was involved in the regulation of Sirt1 and Timp3. WT and NOX2−/− mice were fed with chow, CSAA, CDAA, or WD. Compared to WT mice on chow or CSAA diet, WT CDAA- and WD-fed mice displayed an increase in weight, a significant increase of serum ALT (**P < 0.01, N = 6), and, in CDAA mice, total bilirubin. In NOX2−/− mice, there was no significant increase in ALT or bilirubin. (A). Hematoxylin and eosin staining showed that WT and NOX2−/− mice on CDAA and WD had increased steatosis (B). Lucigenin assay demonstrated significantly increased superoxide production in WT mice on CDAA and WD, compared to those on chow and CSAA diets (*P < 0.05; N = 6). No increase was noted in NOX2−/− mice (*P < 0.05; N = 6) (C and D). SirT1 andTimp3 messenger RNA expression was assessed by real-time qPCR in WT and NOX2−/− mice. SirT1 and Timp3 expression significantly decreased in WT CDAA- (E) and WD-fed mice (F) (**P < 0.01; *P < 0.05, respectively; N = 6). In contrast, in NOX2−/− mice, Sirt1 andTimp3 expression remained unchanged.

Download figure to PowerPoint

ROS production had significantly increased in WT mice on CDAA or WD (Fig. 4C,D; 1.57- ± 0.16-fold; P < 0.05; and 1.75- ± 0.01-fold; P < 0.05), whereas this was attenuated in NOX2−/− mice in both models (to 0.94- ± 0.11-fold and 0.89- ± 0.26-fold; P < 0.05). To correlate the data to humans with NASH, qPCR was performed in all experimental conditions (Fig. 4E,F). WT CDAA- or WD-fed mice showed a significant decrease in Sirt1 (to 0.10- ± 0.04-fold; P < 0.01; and 0.11- ± 0.031-fold; P < 0.05, respectively; N = 6) and Timp3 expression (to 0.21- ± 0.04-fold; P < 0.05; and 0.43- ± 0.01-fold; P < 0.05, respectively; N = 6). In contrast, in NOX2−/− mice, Sirt1 and Timp3 expression was not affected by CDAA or WD.

Correction of Low Timp3 Expression in WT Mice on CDAA or WD by Ad-Timp3 Ameliorates TACE and TNF-α Activity

To confirm the causal link between low Timp3 expression leading to an unopposed increase in TACE activity and consequent induction of TNF-α activity in vivo, we injected Ad-Timp3 or Ad-GFP into WT mice on CDAA or WD. Correcting Timp3 levels resulted in a significant decrease in TACE activity (Fig. 5A,B) and TNF-α activity (Fig. 5C,D) in both diet models. TACE and TNFα activity showed no significant changes in NOX2−/− mice on either diet. Because KCs also express NOX2, a group of mice in both models were also injected by GdCl3 to inhibit the function of these cells and elucidate the respective role of HSCs and KCs in AGEs-induced TACE activation in NASH. Macrophage inhibition did not change TACE activity in either diet model, but showed a decreasing trend for active TNF-α. Triglyceride (TG) content of the liver has significantly increased on both diets in both genotypes, and Ad-Timp3 did not affect TG content (Fig. 5E,F; P < 0.05; N = 6 for each group).

image

Figure 5. Correction of low Timp3 expression by Ad-Timp3 in WT mice on CDAA and WD ameliorated TACE and TNF-α activity. WT mice on CDAA or WD were injected with Ad-Timp3 or Ad-GFP, and TACE activity in the liver was tested. TACE activity significantly increased in WT mice on the CDAA diet, compared to the CSAA group (mean ± SE; *P < 0.05; N = 6), and in WD-fed mice (mean ± SED; *P < 0.05; N = 6). This was significantly attenuated in Ad-Timp3-injected mice in both diets (*P < 0.05; N = 6, each group). NOX2−/− mice did not exhibit an increase in TACE activity on either diet (*P < 0.05; N = 6) (A and B). Gadolinium chloride (Gad) was injected into a group of mice on both diets and genotypes to assess the role of KCs. TACE activity in the liver was not significantly affected by inhibiting the macrophages. TNF-α level was assessed by enzyme-linked immunosorbent assay in the above-described conditions. Compared to the mice on the chow and CSAA diets, WT CDAA-fed or WD-fed mice had significantly higher TNF-α production (*P < 0.05; N = 6), and Ad-Timp3 prevented this induction (*P < 0.05). In NOX2−/− mice on either diet, no increase in TNF-α production was noted (C and D). In Gad-treated mice, there was a trend toward lower TNF-α, albeit not significant. TG content was tested in all groups and both genotypes (E and F). Both diets induced a significant accumulation of TG (*P < 0.05; N = 6); however, this was not improved by lack of NOX2, correcting Timp3 levels, or Gad injection. SE, standard error of mean.

Download figure to PowerPoint

Interestingly, expression of RAGE showed an increase in livers of WT mice on the CDAA diet (2.34- ± 0.17-fold; P < 0.05; Supporting Fig. 2), and this was attenuated by Ad-Timp3 (0.86- ± 0.14; P < 0.05). No increase in RAGE was noted in NOX2−/− mice.

CDAA and WD Induce Fibrogenic Activity in WT Mice, Which Is Attenuated After Ad-Timp3 Injection and in NOX2−/− Mice

Correction of Timp3 may affect fibrogenesis. Therefore, procollagen α1(I), alpha smooth muscle actin (α-SMA), and transforming growth factor beta (TGF-β) were tested by real-time qPCR, and liver tissues were examined after Picro Sirius Red staining and hydoxyproline assay. Procollagen α1(I), α-SMA, and TGF-β expression were significantly elevated both in CDAA-fed (5.91- ± 1.85-fold; P < 0.01; 1.41- ± 0.07-fold; P < 0.01; and 3.37- ± 0.76-fold, respectively; P < 0.05; N = 6; Fig. 6A) and WD-fed mice (1.58- ± 0.12-fold; P < 0.05; 1.75- ± 0.001-fold; P < 0.05; and 1.51- ± 0.13-fold; P < 0.05). Expression of these fibrogenic transcripts significantly decreased after Ad-Timp3 injection in both mouse models: in CDAA-diet–fed mice procollagen α1(I) (to 1.54- ± 0.93-fold; P < 0.05); α-SMA (to 1.05- ± 0.31-fold; P < 0.05); and TGF-β (to 0.96- ± 0.1-fold; P < 0.05). In WD-fed mice after Ad-Timp3 transduction, procollagen α1(I) decreased (to 0.76- ± 0.1-fold; P < 0.05), as did α-SMA (to 0.62- ± 0.09; P < 0.05) and TGF-β (to 0.63- ± 0.1-fold; P < 0.05). These data were confirmed also by the Picro Sirius Red staining and morphometry (Fig. 6C-E) and hydroxyproline assay (Fig. 7). Injection of GdCl3 caused a decrease in expression of α-SMA and TGF-β in the CDAA model, but not in the WD. In NOX2−/− mice on the NASH diets, fibrosis was less pronounced with attenuated procollagen α1(I) and α-SMA expression as well as a significant decrease in Picro Sirius Red positive area (Figs. 6 and 7; P < 0.05) and hydroxyproline quantity (Fig. 7; P < 0.01).

image

Figure 6. CDAA-induced and WD-induced fibrogenic activity is attenuated by Ad-Timp3 injection and also in NOX2−/− livers. Procollagen α1(I), α-SMA, and TGF-β expression was analyzed by real-time qPCR. Messenger RNA levels of these transcripts were significantly increased in CDAA-fed and WD-fed mouse livers injected with the control vector (**P < 0.01; *P < 0.05, respectively; N = 6) and attenuated by Ad-Timp3 injection (*P < 0.05; N = 6). No significant induction of these transcripts was noted in the NOX2−/− group on either diet. Gadolinium injection attenuated the increase in α-SMA and TGF-β in CDAA mice (*P < 0.05; ***P < 0.001), but not in the WD-fed mice (A and B). After picrosirius staining (C) and ImageJ analysis (D) in WT CDAA-fed or WD-fed and control vector-injected mice, the fibrotic area (red, pericellular fibrosis) was significantly increased (*P < 0.05; **P < 0.01; N = 6). In mice injected with Ad-Timp3, the picro sirius–positive area decreased (*P < 0.05). Also, in NOX2−/− mice on both diets, the fibrotic area was significantly lower than in WT mice (expressed as fold compared to samples after chow diet; *P < 0.05; **P < 0.01; N = 6).

Download figure to PowerPoint

image

Figure 7. Hydroxyl proline content decreased after Ad-Timp3 in the CDAA-fed and WD-fed mice. OH-proline incorporation assay was performed to assess the amount of collagen in the liver. Compared to mice on the chow or CSAA diet, CDAA-fed (A) and WD-fed mice (B) displayed a significant increase in OH-proline incorporation (*P < 0.05; N = 6). Ad-Timp3 lowered OH-proline content in WT mice in both models. In NOX2−/− mice, OH-proline incorporation was also significantly lower in both models (*P < 0.05; N = 6).

Download figure to PowerPoint

Discussion

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. References
  7. Supporting Information

IR and DM are major risk factors in the progression of NASH. Several important aspects of the pathogenesis are well defined, but how diabetes creates a proinflammatory and fibrogenic milieu is less clear. Here, we have shown that AGEs/NOX2/ROS-induced decrease in Sirt1 expression in HSCs culminates in an induction of TACE and, consequently, TNF-α activity. Loss of Sirt1 was shown to be associated with metabolic diseases, such as type 2 diabetes, atherosclerosis,[21] and NASH.[21] On the other hand, hepatic Sirt1 deficiency was described to induce IR, and an accumulation of ROS was also detected in the liver.[10] Treating these mice with antioxidants reversed the phenotype, suggesting the key role of ROS in this process. Defining the source of ROS and analyzing the downstream effects of Sirt1 down-regulation are of great importance.

AGEs are formed at a highly accelerated rate during hyperglycemia by a nonenzymatic glycation of serum proteins. The process begins with the conversion of reversible Schiff base adducts to more stable, covalently bound products and, eventually, the irreversibly bound moieties known as AGEs are formed.[22, 23] AGE levels in serum or liver were found to be elevated in patients with steatohepatitis, compared to HCs or patients with simple steatosis.[24] Interaction of AGEs with the associated cell-surface receptor, RAGE, has been linked to induction of OS in the liver,[25] and it was postulated that activation of one of the NOXs was the source of ROS production. However, the specific NOX has not been identified. Here, we described the key role of NOX2 activation in AGE-induced ROS production and the down-regulation of Sirt1/Timp3 pathways. NOX2 is a phagocytic NADPH oxidase, and we and others have shown that it is highly expressed and enzymatically active in HSC during liver fibrosis.[18, 26] NOX2 directly induces HSC activation and production of collagen I by inducing promoter activity by H2O2, and NOX2−/− mice develop significantly less fibrosis in bile duct ligation[18] and CCl4[26] models. AGEs have been described to induce ROS formation by NOXs in other systems,[27, 28] and the postulated mechanism could involve activation of protein kinase C (PKC)-α in the kidney[28] or PKC-δ in neuronal tissue[29] by AGEs. Whether or not in active HSCs other NOXs can elicit a similar response to AGEs could be further investigated in the future. Because p47phox KO HSCs had a decrease in ROS production after incubation with AGEs, it is possible that NOX1 also plays a role as a regulator of Sirt1,[25] because p47phox is a common subunit to both NOX1 and 2. In our study, we demonstrated that, in NOX2−/− mice, there was a significant attenuation of fibrosis on both diets. Because KCs also express NOX2, we treated mice with gadolinium to inhibit their function. We found that this did not interfere with TACE activity in the liver. TACE activity of KCs was not induced by AGEs in vitro and therefore their profibrogenic role during NASH could be attributed to other, more dominant mechanisms, such as Toll-like receptor 4–mediated induction of HSCs.[30] Steatosis was not affected by the lack of NOX2, corresponding to earlier data from the methionine- and choline-deficient model,[31] nor was it influenced by correcting Timp3. This suggests that AGEs mainly induced oxidative and inflammatory pathways in these models. The role of Sirt1 down-regulation in HSCs during NASH progression has not been studied in detail. Because the main source of TACE activity in the liver are activated HSCs,[32] and the natural regulator of TACE is Timp3, we sought to determine whether low Sirt1 could translate into a down-regulation of Timp3 and consequent induction of TACE. First, we confirmed that active HSCs are a potent source of TACE production in the liver and that exposure to AGEs directly induces pathways leading to TACE activation, whereas hepatocytes and KCs do not respond to AGE induction. Second, AGEs induced a NOX2-dependent down-regulation of Sirt1 and Timp3, and both of these transcripts were down-regulated in humans with NASH and also in mice on both diets. Correlating to this, TACE activity was increased by AGEs and also in WT mice on CDAA and WD, but not on the CSAA diet (steatosis). In contrast, no increase in TACE activity was noted in NOX2−/− mice on CDAA and WD, implying that NOX2-derived ROS plays a key a role in TACE activation. To confirm the role of Timp3 in NASH, we injected a group of mice on the CDAA diet with Ad-Timp3. This resulted in a decline in TACE and TNF-α activity as well as RAGE expression. In addition, Ad-Timp3 transduction also improved fibrosis with down-regulation of profibrogenic transcripts and lowering of hydroxyproline content. Because TACE targets multiple other cytokines and chemokines and their receptors,[33] reducing its activity may have led to a decreased production of fibrogenic mediators. For instance, TACE is known to induce ectodomain shedding of fractalkine (CX3CL1)[34]; thus, decrease in fractalkine could have also contributed to the improvement in fibrogenic activity. Mice deficient in Timp3 demonstrated elevated levels of TNF-α and developed IR and hepatic steatosis, mediated by increased TACE activity.[10, 21]

In conclusion, we have demonstrated the central role of the Sirt1/Timp3/TACE cascade in AGE-induced proinflammatory and fibrogenic activity in NASH. Modulation of Timp3 or TACE activity could thus become a successful approach to halt disease progression in NASH.

References

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. References
  7. Supporting Information
  • 1
    Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011;300:G697-G702.
  • 2
    Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-1096.
  • 3
    Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005;1043:452-460.
  • 4
    Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011;24:526-539.
  • 5
    Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002;11:1205-1223.
  • 6
    Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep 2011;11:244-252.
  • 7
    Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010;10:819-823.
  • 8
    Tao R, Wei D, Gao H, Liu Y, DePinho RA, Dong XC. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem 2011;286:14681-14690.
  • 9
    Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med 2011;43:198-211.
  • 10
    Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, Deng CX. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest 2011;121:4477-4490.
  • 11
    Purushotham A, Xu Q, Li X. Systemic SIRT1 insufficiency results in disruption of energy homeostasis and steroid hormone metabolism upon high-fat-diet feeding. FASEB J 2012;26:656-667.
  • 12
    Cardellini M, Menghini R, Martelli E, Casagrande V, Marino A, Rizza S, et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009;58:2396-2401.
  • 13
    Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 2005;115:3494-3505.
  • 14
    Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 2009;136:663-672.e4.
  • 15
    Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009;137:1467-1477.e5.
  • 16
    Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301:G825-G834.
  • 17
    Geerts A, Niki T, Hellemans K, De Craemer D, Van Den Berg K, Lazou JM, et al. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology 1998;27:590-598.
  • 18
    Jiang JX, Venugopal S, Serizawa N, Chen X, Scott F, Li Y, et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology 2010;139:1375-1384.
  • 19
    Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010;139:323-334.e7.
  • 20
    Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50:1152-1161.
  • 21
    Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9:327-338.
  • 22
    Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-10026.
  • 23
    Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
  • 24
    Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:1112-1119.
  • 25
    Guimarãaes EL, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 2010;52:389-397.
  • 26
    Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, et al. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 2011;53:1730-1741.
  • 27
    Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-E694.
  • 28
    Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, Sourris KC, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460-469.
  • 29
    Nitti M, Furfaro AL, Traverso N, Odetti P, Storace D, Cottalasso D, et al. PKC delta and NADPH oxidase in AGE-induced neuronal death. Neurosci Lett 2007;416:261-265.
  • 30
    Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
  • 31
    De Minicis S, Seki E, Paik YH, Osterreicher CH, Kodama Y, Kluwe J, et al. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology 2010;52:1420-1430.
  • 32
    Bourd-Boittin K, Basset L, Bonnier D, L'helgoualc'h A, Samson M, Théret N. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver. J Cell Mol Med 2009;13:1526-1535.
  • 33
    Cerretti DP. Characterization of the tumour necrosis factor alpha-converting enzyme, TACE/ADAM17. Biochem Soc Trans 1999;27:219-223.
  • 34
    Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001;276:37993-38001.

Supporting Information

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. References
  7. Supporting Information

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
hep26491-sup-0001-suppfig1.tif116KSupporting Information Figure 1.
hep26491-sup-0002-suppfig2.tif118KSupporting Information Figure 2.
hep26491-sup-0003-suppfig3.tif112KSupporting Information Figure 3.
hep26491-sup-0004-suppinfo.docx26KSupporting Information
hep26491-sup-0005-suppinfoCap.docx14KSupporting Information Caption
hep26491-sup-0003-supptab1.tif313KSupporting Information Table 1

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.